Z Wang et al. FAP Index.

Development and validation of a novel circulating fibroblast activation
 protein - based predictive model to improve fibrosis risk stratification
 in metabolic liver disease population.

4

Ziqi V Wang<sup>1</sup>, Badwi B Boumelhem<sup>1</sup>, Torsten Pennell<sup>1</sup>, William W Bachovchin<sup>2</sup>, Jack HungSen Lai<sup>2</sup>, Sarah E Poplawski<sup>2</sup>, Pieter Van Der Veken<sup>3</sup>, Kate Brewer<sup>1</sup>, Geraldine Ooi<sup>4</sup>, Jacob
George<sup>5</sup>, Mohamed Eslam<sup>5</sup>, Leon A Adams<sup>6</sup>, Hui Emma Zhang<sup>1</sup>, Geoffrey W McCaughan<sup>1,7</sup>,
Avik Majumdar<sup>1,7,8\*</sup> & Mark D Gorrell<sup>1\*</sup>

9

10 <sup>1</sup>Liver Enzymes in Metabolism and Inflammation, Centenary Institute, and The Faculty of 11 Medicine and Health, The University of Sydney, NSW, Australia; <sup>2</sup>Department of Developmental, Molecular and Chemical Biology, Graduate School of Biomedical Sciences, 12 13 Tufts University, Boston, Massachusetts, 02111, United States; <sup>3</sup>Laboratory of Medicinal 14 Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk, 15 Belgium; Department of Surgery, <sup>4</sup>Monash University, Victoria, Australia; <sup>5</sup>Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of 16 17 Sydney, Westmead, NSW, 2145; <sup>6</sup>Medical School, Faculty of Medicine and Health Sciences, The University of Western Australia, Australia; <sup>7</sup>AW Morrow Gastroenterology and Liver 18 19 Centre, Royal Prince Alfred Hospital, Camperdown, NSW, 2050; <sup>8</sup>Department of 20 Gastroenterology, Austin Hospital, Melbourne, Australia.

21

\*Equal senior and corresponding authors. <u>mark.gorrell@sydney.edu.au;</u>
 <u>avik.majumdar@austin.org.au.</u>

- 24
- 25

# 26 Abstract:

27

## 28 **Objective:**

Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed
to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose
advanced fibrosis in patients with fatty liver disease.

32 Design is preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Z Wang et al. FAP Index.

- 33 Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training
- 34 (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced
- 35 fibrosis (F3-F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic
- 36 cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index,
- 37 containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using
- 38 logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then
- 39 sequential basis.

## 40 **Results:**

- 41 FAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI
- 42 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive
- 43 value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value
- 44 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP
- 45 Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas
- 46 FAP Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate
- 47 results by 70% compared to NFS alone.

## 48 **Conclusion:**

49 FAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in 50 metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates 51 accurate risk-stratification of patients by greatly reducing the frequency of indeterminate 52 results compared to FIB-4 or NFS alone, without compromising negative predictive value.

- 53
- 54

## 55 What is already known on this topic

Fatty liver disease affects one quarter of the global population. Current screening algorithms to triage those at high risk of advanced fibrosis use a dual cut-off approach that results in a proportion of patients that cannot be classified (indeterminate result) and hence need further

- 59 and more costly testing.
- 60 What this study adds

61 We have developed the FAP Index, which is a model using a simple circulating fibroblast 62 activation protein enzyme assay and routinely available clinical variables. Using FAP Index as

- 63 a first-line test followed by the current recommended screening tests (FIB-4 and NFS [NAFLD
- 64 Fibrosis Score]) can reduce indeterminate results by up to 70% compared to the current first-
- 65 line standard of care tests alone, without compromising diagnostic accuracy.

Z Wang et al. FAP Index.

## 66 How this study might affect research, practice or policy

- 67 With recently approved pharmacotherapy for fatty liver disease, improved tools for triaging
- 68 people with metabolic fatty liver disease has increasing urgency. Use of FAP Index could have
- a dramatic effect on screening for advanced fibrosis by reducing fruitless referrals to tertiary
- 70 care and/or further testing. Furthermore, our single-step enzymatic cFAP assay can be adapted
- 71 to point of care or reflex testing settings, allowing for low-cost and high throughput FAP Index
- 72 screening.
- 73

## 74 Keywords:

- 75 Fibrosis, Steatosis, fibroblast activation protein, diagnosis
- 76
- 77 Number of figures: 5
- 78 Number of tables: 4
- 79 Supplemental material.

Z Wang et al. FAP Index.

#### 81

# 82 1 | Introduction

83

84 Fatty liver disease is becoming an increasingly common metabolic disorder and currently affects one quarter of the global population<sup>1, 2</sup>. The pathogenesis of fatty liver disease 85 encompasses multi-factorial causes such as abnormal lipid metabolism, glucose dysregulation, 86 87 gut microbiome alterations and genetic variants<sup>3</sup>. These abnormal physiological changes 88 promote chronic inflammation that can lead to hepatic fibrosis, which is the most potent driver 89 towards end-stage liver disease and hepatocellular carcinoma. Moreover, obesity, type 2 90 diabetes mellitus (T2DM) and insulin resistance drive this disease<sup>4, 5</sup>. Early-stage metabolic 91 fatty liver disease and hepatic fibrosis is usually asymptomatic<sup>6, 7</sup>. However, the risk of liver-92 related morbidity and mortality increases dramatically in parallel with the progression into 93 advanced hepatic fibrosis and cirrhosis<sup>8, 9</sup>. As the presence of advanced fibrosis is the major 94 determinant of liver-related complications, accurately identifying those at risk in the context of 95 increasing metabolic associated fatty liver disease prevalence has become an urgent clinical 96 need for hepatologists, diabetologists and primary care physicians.

97

98 Histological assessment with liver biopsy is becoming less frequently used due to its invasive 99 and inherent sampling bias. New 3D imaging techniques highlight the latter limitation by starkly revealing the uneven localisation of fibrosis<sup>10</sup>. Elastography techniques are not widely 100 101 accessible in the community. Therefore, non-invasive blood tests have come to the forefront for the diagnosis of advanced liver fibrosis in patients with metabolic disorders. The two most 102 commonly used models are the NAFLD fibrosis score (NFS)<sup>11</sup> and the Fibrosis index-4 (FIB-103 104 4)<sup>12</sup>. However, despite being recommended for advanced fibrosis screening, these tests require further optimisation<sup>13, 14</sup>. Recently, the European Association for the Study of the Liver (EASL) 105 106 has proposed a three-step strategy including non-invasive tests (NITs) to screen for advanced fibrosis<sup>15</sup>. This algorithm has been further validated for discriminating advanced fibrosis, 107 108 where it displays superior accuracy to a single test algorithm<sup>8</sup>. Despite the limitations of these NITs, the application of low-cost and simple sequential NITs appears more appropriate to 109 110 screening in the community setting than higher cost alternatives.

111

Fibroblast activation protein alpha (FAP) is a dimeric type 2 trans-membrane glycoprotein with proteolytic activity that degrades fibroblast growth factor 21 (FGF21)<sup>16, 17</sup>, neuropeptide  $Y^{18}$ 

#### Z Wang et al. FAP Index.

114 and denatured collagens<sup>17, 19, 20</sup>, and activates  $\alpha$ 2-antiplasmin<sup>19</sup>. FAP is near-absent from healthy tissues but highly expressed by activated stellate cells and myofibroblasts in cirrhosis<sup>20-</sup> 115  $^{22}$ . Moreover, FAP is heavily glycosylated (~30% by mass), which may confer resistance to 116 degradation that explains the persistence of soluble FAP in circulation (cFAP)<sup>23</sup>. We previously 117 reported our specific enzyme assay of FAP<sup>24, 25</sup>, and have shown that increased cFAP activity 118 associates with advanced fibrosis (F3-F4)<sup>25</sup>. Additionally, cFAP activity decreases following 119 120 liver transplantation<sup>26</sup>. Thus, cFAP activity is a potential serum biomarker for liver fibrosis that 121 derives from the cell types that produce and regulate most of the liver extracellular matrix (ECM)<sup>17, 19</sup>. Moreover, FAP colocalizes with ECM proteins in liver fibrosis<sup>22, 27, 28</sup>. Thus, it is 122 123 important to explore the utility of measuring FAP when assessing fibrosis. FAP can be measured by multiple approaches including specific substrate catalytic assay, antibody capture 124 catalytic assay or ELISA<sup>24, 29-31</sup>. Our robust, single-step in-house FAP assay that uses a FAP-125 specific fluorescent substrate<sup>24</sup> strongly correlates with the commercial ELISA. <sup>24, 26, 29-31</sup> 126 127 In this study, the primary aim was to develop a NIT-based fibrosis algorithm that incorporates 128 our specific, quantitative cFAP enzyme activity assay in patients with metabolic associated

- fatty liver disease to identify advanced fibrosis, and then to validate the performance of this algorithm upon a cohort that mimics a community population. We also examined whether the two most prominent FAP-specific substrates<sup>24, 29</sup> generate comparable quantitative data on FAP abundance in serum samples.
- 133
- 134

# 135 **2 | Method**

136

## 137 2.1 | Study cohorts

138 Two retrospective study cohorts were obtained from their originating hospitals. The training cohort (n=160) consisted of 65 patients who underwent liver biopsy for staging of fatty liver 139 140 disease and 95 patients who had liver biopsy at the time of bariatric surgery at Sir Charles Gairdner Hospital, Perth, Australia and has been described in part previously<sup>32</sup>. The validation 141 142 cohort (n=332) was pooled from two previously described study populations; 182 patients who had liver biopsy at the time of bariatric surgery at The Alfred Hospital, Melbourne, Australia<sup>33</sup> 143 and 150 patients who underwent liver biopsy for fibrosis staging of metabolic associated fatty 144 liver disease (MAFLD) at Westmead Hospital, Sydney, Australia<sup>34</sup>. These cohorts were pooled 145 in order to replicate the prevalence of advanced fibrosis in an at-risk screening population of 146

Z Wang et al. FAP Index.

MAFLD, which is estimated to be 10 to 15% in Australia<sup>35, 36</sup>. All included patients met MAFLD criteria<sup>37</sup> and had available stored serum (-80°C) to perform cFAP assay. <sup>37</sup> The exclusion criteria were (1) alcohol related aetiology (average of >30 grams daily for men and >20 grams daily for women), (2) chronic viral hepatitis and (3) non-metabolic forms of liver disease. Ethics approvals were HREC\_X18-0241 in Sydney Local Health District, 2019/ETH02319 in Westmead Hospital, RGS 01287 in Sir Charles Gairdner Hospital, and 195/15 in The Alfred Hospital.

154

## 155 2.2 | Clinical, demographic and histologic data

Demographic data and routine clinical laboratory values (haematology and biochemistry) were obtained within four weeks of the liver biopsy and measured in standardized units used in Australia. Histological fibrosis assessments were performed for all included patients by the pathology service in each hospital where liver biopsy occurred, as previously described.<sup>32-34</sup> Liver fibrosis grade was evaluated according to the Kleiner pathology scoring system.<sup>38</sup> The outcome variable was advanced liver fibrosis, defined as fibrosis staging >2 (F3-F4). Data were de-identified.

163

## 164 2.3 | The cFAP assay

165 The cFAP assay was performed as previously described<sup>24</sup>. Briefly, 5  $\mu$ L of a 1:5 dilution of 166 either human or mouse serum was pipetted into replicate wells of a 96-well plate and topped 167 up to 70  $\mu$ L with tris-acetate (10 mM)-EDTA (1 mM) (pH 7.4) (TE buffer). Serial dilutions of 168 7-amino-4-methylcoumarin (0-600 pmol) were pipetted in replicate wells to a final volume of 169 100  $\mu$ L per well. The plate was read on a BMG PolarStar plate reader (BMG Labtech, 170 Ortenberg, Germany) set up to read at excitation 355 nm & emission 450 nm every 2.5 mins 171 for 1 hr at 37°C.

172

# 173 2.4 | Statistical analysis

174

175 Data are presented as median with interquartile range (IQR) due to non-parametric distribution 176 and means with standard deviation otherwise. Statistical tests were performed with exclusion 177 of missing data for variables of interest. Mann-Whitney U, one-way ANOVA where 178 appropriate. Linear correlations were assessed with Pearson's correlation coefficient.

#### Z Wang et al. FAP Index.

179 Univariable logistic regression was performed when the dependent variable was binary vs a continuous independent variable.<sup>39</sup> Chi-square test was performed when both dependent and 180 independent variables were non-linear. The distribution of cFAP activity as a continuous 181 182 variable revealed extreme outliers in the training cohort (figure S1). Therefore, cFAP activity 183 was binned into 3 groups (ordinals): 0=low, 1=middle and 2=high using cut-offs at 730 and 1580 pmol AMC/min/mL. The low cut-off was as established by our group previously<sup>25</sup>, and 184 the high cut-off was selected based on optimising specificity for advanced fibrosis. Both 185 continuous and binned cFAP activity were tested for strength of association with advanced 186 fibrosis by binary logistic regression. 187

188

189 To optimise diagnostic accuracy, a multivariable logistic regression model for advanced 190 fibrosis incorporating cFAP and clinical variables was developed following published 191 methods<sup>39</sup>. Variables were selected for multivariable analysis if p < 0.1 on univariable analysis. 192 Backward elimination was then used to arrive at the final model. Interaction between predictors 193 was not accounted in this study. The Hosmer-Lemeshow test was used to assess the goodness of fit of the final model, termed FAP Index. Area under the receiver operating characteristic 194 195 curves (AUROC) were calculated for evaluating diagnostic accuracy of FAP Index in training and validation cohorts. An AUROC greater 0.7 was considered good while a score greater than 196 0.9 is outstanding<sup>40</sup>. Dual cut-off points were chosen from the ROC curve for FAP Index to 197 198 optimize sensitivity and specificity in classifying patients into low- and high-risk of advanced fibrosis, respectively. Positive predictive value (PPV), negative predicted value (NPV)<sup>41</sup>, 199 sensitivity, specificity and accuracy <sup>41</sup> were calculated without the indeterminate population, 200 since that population remained 'unclassified'. FAP index, was compared with FIB-4<sup>12</sup> and 201 202 NFS<sup>11</sup>, both as standalone NITs and as part of sequential NIT combinations. Complete case 203 analysis was applied upon model validation in both training and validation cohorts. FIB-4 and 204 NFS scores were calculated in only 87 patients in the training cohort due to missing data 205 (designated as the training sub-cohort), however, complete data were available for the 206 validation cohort. Delong test was used to compare AUROCs. An alpha value of 0.05 was the 207 threshold for statistical significance. Statistical analyses were performed in R studio (version 208 2023.03.0+386) and GraphPad Prism (GraphPad, v9.4.1).

209

# 210 **3 | Results**

Z Wang et al. FAP Index.

## 212 3.1 | Clinical characteristics of study cohorts

213 Characteristics of study cohorts are presented in table 1 and supplemental table 1. There were 214 no significant differences between the training cohort and the validation cohort except for age, 215 the prevalence of fibrosis stages and cFAP level activities. The training cohort included more 216 advanced fibrosis patients (20.3%) than the validation cohort (11.4%) (P = 0.01). Of note, there 217 was no difference in the prevalence of type 2 diabetes (T2DM), which was 36% in the training 218 and 30% in the validation cohort (P = 0.21). The median body mass index (BMI) also did not 219 differ for the training and the validation cohorts at 38.19 (12.05) and 38.6 (14.2) kg/m<sup>2</sup> respectively (P = 0.89). HOMA-IR is significantly greater in the validation cohort (2.49 (3.18)) 220 compared to the training cohort (0.4 (0.76)) (P < 0.0001). The cFAP activity was greater in the 221 222 validation cohort (1290 (555.9) pmol AMC/min/L) than the training cohort (995.74 (579.3) pmol AMC/min/L) (P < 0.0001). However, there were no significant differences observed for 223 224 liver enzymes. Circulating FAP was found to associate with HOMA-IR, insulin and all three 225 liver transaminases in both cohorts (P < 0.05; supplemental table 2), but cFAP did not associate 226 with T2DM.

227

228 Table 1. Baseline characteristics of training and validation cohort. Statistically significant

229 differences were obtained by Mann-Whitney U test (P-value).

	Training cohort (n=160)	Validation cohort (n=332)	P-value
Age (years)	52 (18.25)	49 (19)	0.02
Gender (Male)	58 (36%)	97 (29.2%)	0.14
Diabetes (1)	57 (36%)	98 (29.6%)	0.21
BMI (kg/m2)	38.19 (12.05)	38.6 (14.2)	0.89
ALT (U/L)	40 (42.25)	44 (45)	0.28
AST (U/L)	32.5 (20)	33 (26.3)	0.87
GGT (U/L)	40 (60.25)	42 (70.3)	0.87
Platelets (PLT; x10 <sup>9</sup> /L)	225 (94)	239 (88.3)	0.11
ALP (U/L)	81 (35.5)	Nd	Nd
Insulin (mU/L)	11 (15)	10 (11)	0.42
HOMA_IR	0.4 (0.76)	2.49 (3.18)	<0.0001
Fibrosis staging			0.02
FO	81 (51.3%)	180 (54.2%)	
F1	35 (22.2%)	84 (25.3%)	
F2	10 (6.3%)	30 (9%)	
F3	17 (10.8%)	29 (8.7%)	
F4	15 (9.5%)	9 (2.7%)	
Advanced fibrosis	32 (20.3%)	38 (11.4%)	0.01
cFAP activity (pmol AMC/min/L)	995.74 (579.3)	1290 (555.9)	<0.0001
cFAP activity ordinal			<0.0001

#### Z Wang et al. FAP Index.

	Level 0	38 (23.8%)	15 (4.5%)	
	Level 1	94 (58.8%)	228 (68.7%)	
_	Level 2	28 (17.5%)	89 (26.8%)	

Notes: Data presented as median (IQR) for continuous variables, and prevalence (%) for categorical variables. #: The value 1 was assigned
 to individuals with type 2 diabetes. BMI, body mass index; ALT, Alanine transaminase; AST, Aspartate transaminase; GGT, Gamma-

232 glutamyl transferase; ALP, alkaline phosphatase; IQR: Interquartile range.

233

## 234 3.2 | FAP Enzyme assay specificity and reproducibility

The specificity of our assay for FAP <sup>24</sup> has been questioned <sup>29</sup> and so was revisited and reaffirmed (supplemental material S2.1; supplemental figure 2). Robust assay reproducibility following freeze/thaw cycles and prolonged ultracold storage were established (supplemental Material S2.2; supplemental figure 3), consistent with our previous data<sup>24, 26</sup>.

- 239
- 240

## 241 3.3 | Application of cFAP for hepatic fibrosis detection

The cFAP activity was significantly associated with fibrosis (supplemental table 2). In particular, cFAP of patients with F3-F4 was significantly greater (P<0.0001) than patients without fibrosis (F0) in the training cohort (figure 1A-B), suggesting an ability to discriminate between absence of fibrosis and presence of advanced fibrosis. Significant differences in cFAP were also observed in inter-stage comparisons with moderate liver fibrosis in the validation cohort.

248

# 249 3.4 | Model development for the detection of advanced fibrosis

Multivariable logistic regression revealed age, T2DM, ALT and cFAP (table 2) as predictors
of advanced fibrosis. We therefore derived FAP Index using the following formula:

252

# 253 FAP Index = -9.499 + 0.101 \* Age + 1.533 \* T2DM (0 or 1) + 0.009 \* ALT + 1.158 \* 254 ordinal\_cFAP (0, 1 or 2)

255

Table 2. Associations between clinical parameters and advanced fibrosis in training cohort. <sup>a</sup>
 Univariate logistic regression; <sup>b</sup> Chi-square test.

	Univariate	e association a	nalysis	Multivari	rriate regression model	
Parameter	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
Age <sup>a</sup>	1.11	1.05-1.16	<0.001	1.11	1.05-1.17	<0.0001

#### Z Wang et al. FAP Index.

Gender (Male) <sup>b</sup>	1.45	0.66-3.19	0.36			
Diabetes (yes/no) <sup>b</sup>	6.92	2.91-16.43	<0.001	4.58	1.68-12.48	<0.001
BMI <sup>a</sup>	0.96	0.91-1.01	0.16			
ALT <sup>a</sup>	1.01	1-1.01	0.01	1.01	1.00-1.02	0.02
AST <sup>a</sup>	1.02	1.01-1.03	0.01			
GGT <sup>a</sup>	1.005	1-1.01	<0.001			
PLT (x10 <sup>9</sup> /L) <sup>a</sup>	0.99	0.98-0.99	<0.001			
ALP <sup>a</sup>	1.02	1.01-1.03	<0.001			
Insulin (mU/L) <sup>a</sup>	1.03	1.01-1.06	0.01			
cFAP activity (pmol AMC/min/L) <sup>a</sup>	1.002	1.0-1.0	<0.001			
Ordinal FAP <sup>b</sup>			<0.001			0.002
0	-	-		-	-	
1	2.27	0.62-8.36		2.42	0.58-10.11	
2	11.67	2.9-46.96		9.24	1.86-46.01	

258 BMI, body mass index; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transaminase; PLT, platelets,

259 ALP, alkaline phosphatase; cFAP, circulating fibroblast activation protein.

260

261 The Hosmer-Lemeshow test  $\chi^2$  was 3.066 (P = 0.93), indicating that FAP Index was well fitted.

262 In the training cohort, the AUROC for FAP Index in predicting advanced fibrosis was 0.875

263 (95% CI: 0.813 – 0.938; figure 2A). Based on the ROC, a dual cut-off strategy was applied to

264 optimise FAP Index for ruling in and out advanced fibrosis. The low cut-off was chosen at -

1.681 (sensitivity = 0.84, specificity = 0.75), and the high cut-off at 0.953 (sensitivity = 0.34, specificity = 0.99). Patients with a score lying in between these low and high cut-off scores were designated indeterminate.

268

The association of FAP Index with fibrosis severity (figure 1C-D) displayed better differentiation across fibrosis stages than with cFAP alone and comparable with FIB-4 (figure 1E-F).

272

# 273 3.5 | Comparison of FAP Index to existing NITs

Only patients with complete data for FAP Index, NFS and FIB-4 were included, which was designated as the training sub-cohort (n=87). The training sub-cohort was compared with its original cohort (supplemental table 2) and was older (57 vs 52, P=0.03), had lower BMI (34 vs 38, P = 0.02) and had higher insulin levels (15 vs 11, P=0.02) and cholestatic liver enzymes. Notably, there was no difference in the prevalence of advanced fibrosis. The FAP Index accuracy was numerically superior to NFS and similar to FIB-4 (AUROC 0.842, 0.779 and

Z Wang et al. FAP Index.

280 0.894, respectively), but without a statistically significant difference between FAP Index and 281 FIB-4 or NFS (figure 2B). The NPVs of FAP Index, NFS and FIB-4 were 95%, 92.6% and 282 95.9%, respectively, with corresponding specificities of 97.7%, 80.6% and 93.8%. The 283 sensitivities of FAP Index, NFS and FIB-4 were between 80 and 85%. Use of FAP Index and 284 FIB-4 as standalone tests resulted in 39.1% and 32.2% of patients classified as indeterminate, 285 respectively, whereas NFS generated 49.4% indeterminate (figure 3A-C, table 3). FAP Index, 286 when considered, as a continuous variable, correlated with both FIB-4 and NFS (P < 0.001; 287 supplemental Material S2.3; supplemental figure 4)

288

289 Table 3. Summary table for these classification analyses of all tests in the training subcohort

290 (*n*=87), reported for NPV, PPV, proportion of indeterminate, sensitivity and specificity. \*:

Test performed	NPV	PPV	% Indeterminate	Sensitivity*	Specificity*
FAP Index	95.5%	88.9%	39.1%	80.0%	97.7%
FIB-4	95.7%	75.0%	32.2%	81.8%	93.8%
NFS	92.6%	64.7%	49.4%	84.6%	80.6%
FAP Index then FIB-4	92.7%	85.7%	20.7%	75.0%	96.2%
FAP Index then NFS	92.3%	88.2%	20.7%	78.9%	96.0%
FIB-4 then FAP Index	94.3%	81.3%	20.7%	81.3%	94.5%
NFS then FAP Index	91.5%	68.2%	20.7%	78.9%	86.0%

291 Sensitivity and Specificity were calculated with the indeterminate results excluded.

292

## 293 3.6 | FAP Index validation

The AUROC for FAP Index to predict advanced fibrosis in the validation cohort was 0.841 294 (figure S5). In the validation cohort, FAP Index and FIB-4 produced similar outcomes, with 295 296 specificity above 98%, which were superior to NFS (specificity 64.4%). The NPVs for all three 297 tests were above 90% (figure 4A-C, table 4). The FIB-4 sensitivity was 37.5%, while 298 sensitivities for FAP Index and NFS were over 50%. Importantly, all tests exhibited large 299 proportions of indeterminate: 32.6% for FAP Index, 24.1% FIB-4 and 47.5% for NFS. FAP 300 Index was significantly correlated with FIB4 and NFS in the validation cohort (P < 0.0001; 301 supplemental figure 4).

302

303 *Table 4.* Summary table for these classification analyses of all tests in the validation cohort,

304 reported for NPV, PPV, proportion of indeterminate, sensitivity and specificity. \* Sensitivity

305 *and Specificity were calculated with the indeterminate results excluded.* 

Z Wang et al. FAP Index.

Test performed	NPV	PPV	% Indeterminate	Sensitivity*	Specificity*
FAP Index	97.5%	66.7%	32.6%	54.5%	98.5%
FIB-4	95.7%	66.7%	24.1%	37.5%	98.7%
NFS	93.2%	15.9%	47.5%	58.8%	64.4%
FAP Index then FIB-4	96.4%	64.3%	16.8%	50.0%	98.0%
FAP Index then NFS	95.7%	29.7%	14.9%	52.4%	89.5%
FIB-4 then FAP Index	95.6%	58.3%	16.8%	38.9%	98.0%
NFS then FAP Index	96.0%	19.4%	14.9%	61.9%	78.2%

<sup>306</sup> 

## 307 3.7 | Sequential application of NITs

308 Next, sequential application of each possible combination of NITs was performed, with the 309 primary aim to minimize the proportion of patients who were indeterminate without compromising diagnostic accuracy (figure 5). All combinations and sequences of NITs 310 generated similar NPVs, above 90%, in both training cohort (table 3) and validation cohort 311 (table 4). In the training cohort, FAP Index applied as either the 1<sup>st</sup> line or 2<sup>nd</sup> line NIT in 312 combination with either NFS or FIB-4 reduced the proportion of indeterminate to 20.7% (figure 313 314 3D-G; table 3). In the validation cohort, FAP Index used in combination with NFS resulted in 315 14.9% indeterminates, whereas FAP Index with FIB-4 in any combination led to 16.8% indeterminates (table 4, figure 4D-G). In both cohorts, the relative reduction in the 316 317 indeterminate population caused by adding the second line test reached 50%. However, 318 combinations of FAP Index with FIB-4 followed by FAP Index maintained specificity of ~95% 319 in both cohorts (98% in validation cohort) compared to NFS combinations with FAP Index 320 where specificity was as low as 78% in the validation cohort (tables 3 and 4). This is reflected 321 in figure 4, where although NFS combinations classified more patients as high risk, up to 80% 322 did not have histologic advanced fibrosis. Importantly, applying a step-wise test approach did not influence the sensitivity and PPV compared with applying a single test. Sensitivity was 323 324  $\sim$ 75% in the training cohort, and  $\sim$ 50% in the validation cohort. As expected in the validation 325 cohort where the prevalence of advanced fibrosis was lower, NPV increased and PPV reduced 326 compared to the training sub-cohort. Overall, the combination of FAP Index followed by FIB-327 4 generated the optimal diagnostic metrics, sufficiently reducing indeterminate results while 328 maintaining an excellent NPV and acceptable PPV compared to single NITs.

329

# 330 4 Discussion

#### Z Wang et al. FAP Index.

332 In this study, we demonstrated that circulating fibroblast activation protein (cFAP), a marker of activated stellate cells and myofibroblasts, can be incorporated into an algorithm and applied 333 334 following NFS or FIB-4 to greatly diminish the number of indeterminate outcomes without 335 compromising sensitivity or specificity for advanced hepatic fibrosis. This novel NIT, which 336 we call FAP index, was examined in a training cohort and validated in a pooled cohort of 337 individuals with metabolic fatty liver disease with variable prevalence of biopsy proven 338 advanced fibrosis, type 2 diabetes, obesity and metabolic syndrome. The FAP Index utilises 339 cFAP and three routinely obtained parameters; age, T2DM status and ALT. We have demonstrated the combination of FAP Index followed by FIB-4 provides a significant 340 341 reduction in indeterminate results without compromising diagnostic accuracy.

342

Of the variables included in FAP Index, ALT is a well-established biomarker for the severity 343 of liver injury: age is a known risk factor for progression for liver disease.<sup>42</sup> T2DM and insulin 344 resistance are drivers of metabolic fatty liver disease progression, and insulin resistance 345 increases intrahepatic oxidative stress<sup>3, 5, 43, 44</sup>. The presence of these variables suggests a 346 dysmetabolic state with liver injury resulting in continual hepatic stellate cell (HSC) activation. 347 We have shown that FAP is strongly associated with the presence of advanced fibrosis<sup>20-22, 25</sup>, 348 and FAP is found in and on activated HSC and myofibroblasts and contributes to collagen 349 turnover<sup>20, 21</sup>. Moreover, new FAP/<sup>42</sup>radionuclide-based 3D imaging methods have shown that 350 intrahepatic FAP strongly aligns with fibrosis severity<sup>10</sup>. Serum FAP drops following liver 351 transplantation<sup>26</sup>, which suggests that liver is the origin of increased circulating FAP in patients 352 353 with advanced fibrosis.

354

In the training sub-cohort, FAP Index showed excellent accuracy in predicting the presence of advanced fibrosis, with an AUROC of 0.875 (95% CI: 0.813-0.938), while FIB-4 and NFS achieved comparable AUROCs of 0.899 (95% CI: 0.833-0.965) and 0.781 (95% CI: 0.672-0.89) respectively. Our findings demonstrated that the FAP Index has a strong discriminating capability among cohorts of varied patient composition and prevalence of advanced fibrosis. However, the percentage classified as indeterminate was relatively large as standalone NIT, which is an established issue for FIB-4 and NFS.

362

In contrast, sequentially using FAP Index with either FIB-4 or NFS was shown to dramatically
 reduce the number of indeterminate results by between 30% and 70%, depending on the NIT

#### Z Wang et al. FAP Index.

combination. <sup>13, 45</sup> Notably, the two-step strategy did not significantly alter the NPV, PPV nor 365 specificity when using FAP Index as either 1<sup>st</sup> line test or 2<sup>nd</sup> line test in combination with 366 either FIB-4 or NFS. Indeed, our group and others have shown that sequential screening tests 367 368 that employ dual cut-offs can the increase diagnostic accuracy of NITs and thereby reduce the number of biopsy referrals<sup>46-48</sup>. Similarly, a recent evaluation of the current EASL algorithm 369 by Patel and colleagues found that a stepwise strategy can improve diagnostic accuracy<sup>8</sup>. 370 However, the use of FIB-4 or NFS as first line NITs resulted in approximately 35% and up to 371 372 65% indeterminate results, respectively, in both the diabetes clinic and primary care cohorts 373 analysed. Furthermore, up to 84% needed further assessment (ie indeterminate or high-risk classification) when using NFS or FIB-4<sup>8</sup>. In contrast, our two-step algorithm of FAP Index 374 followed by FIB-4 resulted in 39% in the training subcohort and only 21% in the validation 375 376 cohort who would need further investigation by the same criteria (ie indeterminate or high-risk 377 classification). This reduction compared to the Patel study was in the context of similar 378 advanced fibrosis prevalence in our training subcohort of 27%, however only 48 patients 379 underwent biopsy in the Patel cohorts.

380

Another advantage of the sequential combination of FAP Index with FIB-4 was the high 381 specificity. It is essential to make sure that false positives and, particularly in the context of 382 383 screening, that false negatives are minimized. Our validation cohort had a prevalence of advanced fibrosis similar to the community of 11%<sup>35, 36</sup> and using FAP Index followed by FIB-384 385 4 resulted in 3.6% (9/249) false negatives and 35.7% (5/14) false positives. This strategy provided the lowest rate of false negative diagnoses and comparable false positives to FIB-4 386 and NFS, in addition to the dramatic reduction in indeterminate results. This suggests that FAP 387 388 Index has potential benefit in community screening algorithms over current standard of care.

389

FAP Index has potential as a readily applicable first line test as it contains variables that are easily obtained, and cFAP measurement requires only a standard fluorescence measurement device, so its cost is likely to be comparable with AST and ALT. Similarly, the measurement of ordinal cFAP in FAP Index could be readily modified into a point-of-care lateral flow test, or as a reflex test during the measurement of liver biochemistry as part of clinical pathology services.

#### Z Wang et al. FAP Index.

397 Community demand for screening for hepatic fibrosis is rising, particularly in diabetes clinics, so inexpensive, simple liver fibrosis testing is needed. Although biopsy is considered as the 398 399 most accurate diagnostic tool in clinical guidelines, it has unavoidable pitfalls such as 400 accessibility, invasiveness, the need for specialised staff, variability between practitioners, and 401 economic impacts. While elastography is a useful alternative to biopsy, accuracy drops when BMI exceeds 44, and it is influenced by operator-dependent variables and barriers still exist in 402 403 terms of accessibility and/or affordability<sup>49</sup>. Therefore, the potential for FAP Index as an 404 accurate blood test and point-of-care test in routine screening could alleviate total health care 405 costs. More importantly, the enzyme activity of soluble FAP was found to have high stability with extended ultracold storage <sup>24</sup> (supplemental figure2), which means that the cFAP assay is 406 407 amenable as a subsequent test after an initial FIB4 or NFS is completed. Thus, FAP Index as a 408 reflex test would not require an additional blood collection, which further increases 409 convenience and reduces health care expenditures.

410

411 Following a successful clinical trial<sup>50</sup>, the U.S. Food and Drug Administration recently 412 approved a thyroid hormone receptor beta (THR- $\beta$ ) agonist<sup>51</sup> as the first therapy for noncirrhotic steatohepatitis and advanced stages of liver fibrosis. This further motivates the need 413 for more accurate triage of patients with advanced fibrosis. NFS and FIB-4 are currently 414 415 regarded as standard of care for fibrosis screening, however, these NITs rely upon parameters that are strongly associated with liver function, liver injury and inflammation, rather than 416 directly with fibrosis per se<sup>11, 12</sup>. As a result, these tests can yield large proportions of 417 misclassifications among patients at high risk of metabolic fatty liver disease<sup>14</sup>. Liver fibrosis 418 419 is dependent on the intensity of tissue remodelling and myofibroblast activation. Therefore, 420 including a simple biomarker such as FAP that directly reflects the fibrotic process is 421 advantageous.

422

423 A major strength of this study was the robust training and validation cohorts. The prevalence 424 of fibrosis in the training cohort was similar to that of hepatology clinic populations, while the 425 validation cohort mimics community screening in an at-risk population, albeit with high 426 frequencies of obesity and diabetes. We have demonstrated that our FAP assay is robust and 427 activity can be measured via a robust and simple one-step enzyme assay. We used validated 428 methodology to arrive at the FAP Index and have performed comprehensive statistical analysis 429 to examine the influence of using different NITs alone or in combination. The study limitations

Z Wang et al. FAP Index.

430 were sample selection, sample size and non-centralised histologic fibrosis assessment.

431 Comparison of NITs in the training cohort were only available in a subset of patients, however,

432 the findings were replicated in the validation cohort.

433

# 434 **5 | Conclusion**

We have developed and validated FAP Index; a simple and novel non-invasive test for triaging 435 436 the risk of advanced fibrosis in metabolic associated fatty liver disease. FAP Index 437 demonstrated excellent diagnostic accuracy with an AUROC of 0.875 as a standalone test. However, sequential use of FAP Index followed by FIB-4 yielded more favourable results with 438 439 a reduction of indeterminately classified patients by one third compared to FIB-4 alone in both 440 training and validation cohorts. This was achieved while maintaining an NPV of >95% and 441 having the lowest percentage of false negative diagnoses of any NIT strategy examined. 442 Moreover, FAP Index used sequentially with NFS compared to NFS alone generated even more 443 striking results. FAP Index includes a direct marker of fibrogenesis (cFAP), which is simple 444 and inexpensive to measure with potential application as a point of care or reflex test. Therefore, 445 FAP Index demonstrates several advantages over the current first-line standard of care NITs 446 for triaging risk of advanced fibrosis due to MAFLD and should be developed for clinical use.

Z Wang et al. FAP Index.

#### 448 **ABBREVIATIONS**

449

477

478

479

480

450	ALP, alkaline phosphatase; ALT, Alanine transaminase; APRI, AST to Platelet Ratio Index;
451	AST to Platelet Ratio Index; AST, Aspartate transaminase; AUROC, area under the receiver
452	operating characteristics curve; BMI, body mass index; cFAP, circulating fibroblast
453	activation protein; ECM, extracellular matrix; ESAL, equivalent single axle load; FAP,
454	fibroblast activation protein; FGF-21, fibroblast growth factor 21; GGT, Gamma-glutamyl
455	transferase; HSC, hepatic stellate cell; IQR, inter-quartile range; MAFLD, metabolic
456	associated fatty liver disease; MRE, magnetic resonance elastography; NFS, NAFLD Fibrosis
457	Score; NIT, non-invasive test; NPV, negative predictive value; PLT, platelet; PPV, positive
458	predictive value; ROC, receiver operating characteristics curve; T2DM, type 2 diabetes
459	mellitus.
460	
461	FINANCIAL SUPPORT
462	
463	This project was funded under Australian National Health and Medical Research Council
464	project grant 1105238 (MDG, GWM, WWB), a Rebecca L Cooper Medical Research
465	Foundation (MDG) grant, Centenary Institute Foundation (MDG) and a Gilead Fellowship
466	(AM). JG is supported by: the Robert W. Storr Bequest to the Sydney Medical Foundation,
467	University of Sydney; a National Health and Medical Research Council of Australia
468	(NHMRC) Program Grant (APP1053206); Project, Ideas and Investigator grants
469	APP2001692, APP1107178, APP1108422 and APP1196492; and a Cancer Institute NSW
470	grant (2021/ATRG2028). LAA received research grant funding from the Hollywood Private
471	Hospital Research Foundation and the Sir Charles Gairdner Osborne Parke Health Care
472	Group.
473	
474	AUTHOR CONTRIBUTIONS
475	
476	ZVW: study concept and design, statistical analysis, analysis and interpretation of data, drafting

the manuscript; BBB: acquisition of data, review and manuscript editing, study supervision;

TP: study concept, statistical analysis; WWB, SEP, JHSL, PVDV, JG, LAA: Supply study

materials, critical revision of the manuscript; GO, ME: acquisition of study samples; KB:

statistical analysis and interpretation of data; HEZ: study concept and design, statistical

Z Wang et al. FAP Index.

481	analysis; GWM: acquisition of study samples, obtained funding; AM: study concept and design,
482	critical revision of the manuscript for important intellectual content, study supervision; MDG:
483	study concept and design, obtained funding, critical revision of the manuscript for important
484	intellectual content, study supervision.
485	
486	DATA AVAILABILITY STATEMENT
487	
488	All data can be achieved from corresponding authors of this paper upon reasonable request.
489	
490	Competing interests All authors declared to have no conflict of interest to this project.
491	
492	Patient and public involvement Patients and/or the public were not involved in the design,
493	or conduct, or reporting, or dissemination plans of this research.
494	
495	Patient consent for this publication, Consent was not required from patients.
496	
497	Ethics approval. The approvals were HREC_X18-0241 in Sydney Local Health District,
498	2019/ETH02319 in Westmead Hospital, RGS01287 in Sir Charles Gairdner Hospital, and
499	195/15 in The Alfred Hospital. All participants provided written informed consent and their
500	serum samples and information were handled in accordance with ethics approvals and
501	attendant regulations of each hospital.
502	
503	Supplemental material This content has been supplied by the authors.
504	
505	ORCID IDs
506	Ziqi V Wang https://orcid.org/0009-0005-2725-4689
507	Badwi Boumelhem https://orcid.org/0000-0002-1158-123X
508	William Bachovchin https://orcid.org/0000-0002-9926-7244
509	Geraldine Ooi https://orcid.org/0000-0002-4540-408X
510	Jacob George https://orcid.org/ <u>0000-0002-8421-5476</u>
511	Leon Adams https://orcid.org/0000-0002-3968-7909
512	Peter van der Veken https://orcid.org/0000-0003-1208-3571
513	Hui Emma Zhang https://orcid.org/0000-0002-4699-4237

Z Wang et al. FAP Index.

- 514 Geoff McCaughan https://orcid.org/0000-0002-1483-1636
- 515 Avik Majumdar <u>https://orcid.org/0000-0003-2975-4327</u>
- 516 Mark Gorrell <u>https://orcid.org/0000-0002-0528-2604</u>

Z Wang et al. FAP Index.



520 Figure 1. Associations of cFAP activity, FAP Index and FIB-4 with fibrosis staging. The

- 521 cFAP activity (U/L) (A, B), FAP Index (C, D) and FIB-4 (E, F) segregated according to
- 522 fibrosis stage are displayed for training cohort (n=160) (A, C, E) and validation cohort (n=160)
- 332) (B, D, F). Dot plots with mean  $\pm$  SEM. Differences between groups were determined 523
- 524 using a one-way ANOVA with Tukey's post-hoc test. Significant differences are indicated

Z Wang et al. FAP Index.

- 525 with asterisks to indicate degree of difference: \* p-value<0.05, \*\* p-value<0.01, \*\*\* p-
- 526 value<0.001, \*\*\*\* p-value<0.0001.

Z Wang et al. FAP Index.



528

Z Wang et al. FAP Index.

- 529 *Figure 2.* (*A*) The receiver operating characteristics curve for the FAP Index in the training
- 530 *cohort* (AUROC = 0.875 *with* 95% CI: 0.757 0.927). (B) *The* AUROC for the FAP Index is
- 531 *comparable with FIB-4 and NFS. Receiver operating characteristics curve of test scores in the*
- 532 training cohort subset including FAP Index (AUROC = 0.842 with 95% CI: 0.757-0.927), FIB-
- 533 *4 (AUROC = 0.894 with 95% CI: 0.825-0.963) and NFS (AUROC = 0.779 with 95% CI: 0.67-*
- 534 0.889). Statistical significance between ROC curves was tested by DeLong test.





Z Wang et al. FAP Index.

Figure 3. Classification analyses in training cohort. Fibrosis stages classification as single test or sequential tests, as a function of subgroups defined by: A. FAP Index classification. B. FIB-4. C. NAFLD Fibrosis Score. D. FAP Index followed by FIB-4. E. FAP Index followed by NAFLD Fibrosis Score. F. Fibrosis stages as a function of subgroups defined by FIB-4 followed by FAP Index. G. NAFLD Fibrosis Score followed by FAP Index.





Z Wang et al. FAP Index.

Figure 4. Classification analysis in the validation cohort. Fibrosis stages classification as a single test or sequential tests, as a function of subgroups defined by A. FAP Index classification.
B. FIB-4. C. NAFLD Fibrosis Score. D. FAP Index followed by FIB-4. E. FAP Index followed by NAFLD Fibrosis Score. F. FIB-4 followed by FAP Index. G. NAFLD Fibrosis Score followed by FAP Index.

Z Wang et al. FAP Index.



*Figure 5.* Flowchart for model validation in all cohorts, using two sequential tests to further classify the indeterminate patients from the  $1^{st}$  line screening test.

Z Wang et al. FAP Index.

# References

1. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. Epub 2017/03/01.

 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol.
 2021;18(4):223-38. Epub 2020/12/23.

3. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. Epub 2016/01/30.

4. Fujii H, Kawada N, Japan Study Group Of Nafld J-N. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020;21(11). Epub 2020/06/04.

5. Tanase DM, Gosav EM, Costea CF, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020:3920196. Epub 2020/08/25.

6. Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7(11):1450-9. Epub 2015/06/19.

7. Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis. 2016;20(2):293-312. Epub 2016/04/12.

8. Canivet CM, Costentin C, Irvine KM, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology. 2023;77(3):920-30. Epub 2022/07/14.

9. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-65. Epub 2017/01/29.

10. Li H, Dai R, Huang Y, et al. [18F]AlF-ND-bisFAPI PET imaging of fibroblast activation protein as a biomarker to monitor the progression of liver fibrosis. Hepatology Communications. 2024;8(4):e0407.

11. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. Epub 2007/03/30.

12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. Epub 2006/05/27.

13. Ismaiel A, Leucuta DC, Popa SL, et al. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and metaanalysis. Panminerva Med. 2021;63(4):508-18. Epub 2020/11/10.

14. Graupera I, Thiele M, Serra-Burriel M, et al. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2022;20(11):2567-76 e6. Epub 2022/01/01.

15. Panel EAftSotLCPG. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatology. 2021;75(3):659-89. Epub 2021/06/25.

16. Coppage AL, Heard KR, DiMare MT, et al. Human FGF-21 Is a Substrate of Fibroblast Activation Protein. PLoS One. 2016;11(3):e0151269. Epub 2016/03/11.

Z Wang et al. FAP Index.

17. Zhang HE, Hamson EJ, Koczorowska MM, et al. Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. Mol Cell Proteomics. 2019;18(1):65-85. Epub 2018/09/28.

18. Wong PF, Gall MG, Bachovchin WW, et al. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. Peptides. 2016;75:80-95. Epub 2015/12/02.

19. Christiansen VJ, Jackson KW, Lee KN, et al. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys. 2007;457(2):177-86. Epub 2006/12/19.

20. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29(6):1768-78. Epub 1999/05/29.

21. Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver Internat. 2002;22(2):93-101. Epub 2002/05/25.

22. Wang XM, Yu DM, McCaughan GW, et al. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005;42(4):935-45. Epub 2005/09/22.

23. Lay AJ, Zhang HE, McCaughan GW, et al. Fibroblast activation protein in liver fibrosis. Front Biosci. 2019;24(1):1-17. Epub 2018/11/24.

24. Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio. 2013;4:43-54. Epub 2013/12/29.

25. Williams KH, Viera de Ribeiro AJ, Prakoso E, et al. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract. 2015;108(3):466-72. Epub 2015/04/04.

26. Uitte de Willige S, Keane FM, Bowen DG, et al. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS One. 2017;12(6):e0178987. Epub 2017/06/06.

27. Gorrell MD, Wang XM, Levy MT, et al. Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection. Adv Exp Med Biol. 2003;524:235-43. Epub 2003/04/05.

28. Cox G, Kable E, Jones A, et al. 3-dimensional imaging of collagen using second harmonic generation. J Struct Biol. 2003;141(1):53-62. Epub 2003/02/11.

29. De Decker A, Vliegen G, Van Rompaey D, et al. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). ACS Med Chem Lett. 2019;10(8):1173-9. Epub 2019/08/16.

30. Song P, Pan Q, Sun Z, et al. Fibroblast activation protein alpha: Comprehensive detection methods for drug target and tumor marker. Chemico-Biological Interactions. 2022;354:109830.

31. Bainbridge TW, Dunshee DR, Kljavin NM, et al. Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Sci Rep. 2017;7(1):12524. Epub 2017/10/04.

Z Wang et al. FAP Index.

32. Adams LA, Wang Z, Liddle C, et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2020;40(6):1356-65. Epub 2020/04/04.

33. Ooi GJ, Earnest A, Kemp WW, et al. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. Int J Obes (Lond). 2018;42(11):1900-11. Epub 2018/02/22.

34. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019;69(3):1075-86. Epub 2018/07/18.

35. Adams LA, Roberts SK, Strasser SI, et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. Journal of Gastroenterology and Hepatology. 2020;35(9):1628-35.

36. Roberts SK, Majeed A, Glenister K, et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. Medical Journal of Australia. 2021;215(2):77-82.

37. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunctionassociated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. Epub 2020/04/12.

38. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. Epub 2005/05/26.

39. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51(10):1867-73. Epub 2005/08/02.

40. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315-6. Epub 2010/08/26.

41. Parikh R, Mathai A, Parikh S, et al. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45-50. Epub 2007/12/26.

42. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. Epub 2017/09/21.

43. Marusic M, Paic M, Knobloch M, et al. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827. Epub 2021/03/09.

44. Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. Int J Gen Med. 2021;14:1349-55. Epub 2021/04/24.

45. Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067. Epub 2020/03/03.

46. Crossan C, Majumdar A, Srivastava A, et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver international : official journal of the International Association for the Study of the Liver. 2019;39(11):2052-60. Epub 2019/07/25.

47. Majumdar A, Campos S, Gurusamy K, et al. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. Hepatology. 2020;71(2):627-42. Epub 2019/07/13.

Z Wang et al. FAP Index.

48. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-19. Epub May 2021.

49. Eilenberg M, Munda P, Stift J, et al. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr. 2021;10(5):610-22. Epub 2021/11/12.

50. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. Epub 2024/02/07.

51. Hu L, Gu Y, Liang J, et al. Discovery of Highly Potent and Selective Thyroid Hormone Receptor beta Agonists for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2023;66(5):3284-300. Epub 2023/02/18.